Amylyx Pharmaceuticals (AMLX) just posted its third quarter update, with net loss for the period at US$45.49 million and basic loss per share at US$0.38, keeping profitability in sharp focus for investors.
Amylyx Pharmaceuticals’ share price has been on a strong run, with a 90-day share price return of 38.05% and a year-to-date share price gain of 161.47% to US$29.86. The 1-year total shareholder return of 140.42% signals momentum building despite the wider quarterly loss.
Spot 20 high quality undiscovered gems that share Amylyx Pharmaceuticals’ mix of high price momentum and early-stage development risk across the broader market.Bulls point to Amylyx Pharmaceuticals’ sharp share price surge and clinical pipeline, while bears highlight the widening quarterly loss and lack of revenue. Which story do the current valuation markers lean toward next?
Most Popular Narrative: 30% Undervalued
Amylyx Pharmaceuticals is trading at $29.86 against an analyst consensus Narrative fair value of $42.36, which frames the stock as materially undervalued based on that model. The analyst consensus Narrative on Simply Wall St ties that gap to a detailed view of future earnings, margins and risks using a 7.24% discount rate.
The analysts have a consensus price target of $42.36 for Amylyx Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $57.0, and the most bearish reporting a price target of just $20.0.
See why 3 investors see Amylyx Pharmaceuticals as 30% undervalued.
On those assumptions, the Narrative leans on ambitious forecasts. It assumes revenue reaching $343.4m by September 2029, earnings of $86.8m, and a 25.3% profit margin for Amylyx Pharmaceuticals, then discounts those future cash flows at 7.24% to reach today’s fair value. To align with the $42.36 fair value, the shares would also need to trade on a P/E of 70.0x those projected 2029 earnings. This is far above the current 15.8x P/E cited for the broader US pharmaceuticals group in the same Narrative.
For you as a shareholder or prospective buyer, the tension is clear. The model is supportive of upside, yet it concentrates a lot of weight in a single asset, avexitide, and in the broader post bariatric hypoglycemia and rare disease pipeline progressing largely as expected. The same report explicitly encourages investors to stress test those inputs against their own expectations, particularly around how quickly a first commercial product could scale, what pricing and access might look like and how dependent the future earnings profile is on one treatment area.
Result: Fair Value of $42.36 (UNDERVALUED)
Still, Amylyx Pharmaceuticals relies heavily on avexitide and the LUCIDITY Phase 3 outcome, and any regulatory or commercial setback could quickly undercut that undervaluation story.
Find out about the key risks to this Amylyx Pharmaceuticals narrative.
Next Steps
Mixed signals on Amylyx Pharmaceuticals so far. Act while the data is fresh, pressure test the bullish and bearish assumptions yourself, then weigh the 2 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Amylyx Pharmaceuticals?
If you stop at Amylyx Pharmaceuticals, you risk missing other opportunities that line up better with your goals, risk tolerance and income needs.
- Chase potential upswings in smaller companies by scanning a focused set of 11 elite penny stocks with strong financials that already clear strict financial quality checks.
- Zero in on opportunities where price lags business strength by using the 32 high quality undervalued stocks to target quality first, valuation second.
- Prioritise resilience and balance sheet strength by working through a curated list of solid balance sheet and fundamentals (23 results) before the crowd pays closer attention.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com